Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507

Tel :+91 40 4900 2900
Fax :+91 40 4900 2999
Email :mail@drreddys.com
www.drreddys.com

April 4, 2022

Kind Attn.:
Mr. Binoy Yohannan,
Chief Manager, Surveillance,
The National Stock Exchange of India Ltd.

Sub: Clarification /Confirmation on news item appearing in "Media/Publication"

Dear Sir(s),

This is with reference to your email dated April 1, 2022 regarding news item captioned "Himachal Pradesh high court restrains DRL from selling BI's diabetic drug Jardiance".

In this connection, we would like to clarify the following:

- On October 16, 2021, the Company filed a patent revocation petition before the Hon'ble High Court of Delhi to challenge the validity of the existing patent of Boehringer Ingelheim on Jardiance (empagliflozin) in India. The Company also attempted to launch an affordable version of empagliflozin.

- Thereafter, Boehringer Ingelheim filed a petition before the Hon'ble High Court of Himachal Pradesh, *inter alia* for grant of permanent injunction against the Company against dealing in above patented product. Hon'ble High Court granted an *ex-parte* ad-interim injunction against the Company vide its order dated October 20, 2021, restraining to deal in the patented product of Boehringer Ingelheim, as stated in the Order, till the date of next hearing.

- The Hon'ble High Court of Himachal Pradesh at their hearing held on March 11, 2022, has made the above ad-interim protection absolute during the pendency of the civil suit filed by Boehringer Ingelheim, subject to any further order(s) which may be passed by the Hon'ble High Court.

- The Company is seeking legal opinion in the matter *and will continue to take all appropriate and timely action. The Company has filed an appeal against the March 11 order at the* Hon'ble High Court of Himachal Pradesh.

In view of the ad-interim injunction of the Hon'ble High Court, the Company has not dealt with the said product. Please note that the Company is not aware of any information in this regard which requires disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Please also note that there is no material impact of the news article on the Company.

Further, we remain committed to ensuring affordability and access to the patient population in India and across the world in line with our purpose of "Good Health Can't Wait'."

Kindly take the above on record.

Thanking you.

Yours faithfully,
For **Dr. Reddy's Laboratories Limited**

KUMAR RANDHIR SINGH
Digitally signed by KUMAR RANDHIR SINGH
Date: 2022.04.04 20:25:05 +05'30'

K Randhir Singh
Company Secretary & Compliance Officer